The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
FDA Approves Sale of UTI Antibiotic
The FDA has approved pivmecillinam, an antibiotic for the treatment of urinary tract infections (UTIs) in women, according to The New York Times. The drug, which has been used in Europe for more than 40 years, will be marketed in the US as Pivya and will be available by prescription to women 18 years and older. This is the first time in 2 decades that the FDA has approved a new antibiotic for UTIs. Consequently, this gives health providers a new tool to combat UTIs, which have become increasingly unresponsive to existing antimicrobial drugs. Utility Therapeutics, the US company that acquired the rights to pivmecillinam, said it would be available in 2025 and that it is seeking FDA approval for an intravenous version of the drug for more serious infections, which would usually be administered in a hospital setting.
Senate Committee Investigates Ozempic, Wegovy Pricing
A Senate committee is launching an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs, Ozempic and Wegovy, according to Reuters. Senator Bernie Sanders (I-VT), chair of the Senate Committee on Health, Education, Labor, and Pensions, sent a letter to Novo Nordisk’s CEO seeking more information on US prices for the drugs, which are higher than those in other countries. Additionally, the committee asked why Novo Nordisk was charging a higher price for Wegovy than Ozempic despite both containing the same compound; the drugs are considered GLP-1 agonists as they both reduce food cravings and cause the stomach to empty more slowly. The committee also asked if Novo Nordisk will substantially reduce both the list and net prices of both drugs.
US Births Fell Last Year After Previous Pandemic Rebound
US births fell last year, resuming a national slide after a previous increase during the pandemic, according to The Associated Press. The CDC released provisional statistics on Thursday, which showed that just under 3.6 million babies were born in 2023; this was about 76,000 fewer than in 2022 and the lowest 1-year tally since 1979. Birth rates fell across most racial and ethnic groups: 5% for American Indian and Alaska Native women, 4% for Black women, 3% for White women, and 2% for Asian American women; conversely, births rose by 1% for Hispanic women. Overall, births had been slipping for over a decade before the COVID-19 pandemic hit, and they dropped 4% from 2019 to 2020. However, births then increased for 2 straight years, which experts partially attributed to pregnancies that couples had put off amid the early days of the pandemic. After the release of the 2023 numbers, experts reported that the US is back to the previous downward trend.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Challenges in developing next-generation cancer therapies persist; research indicates widespread utilization and hurdles in affordability and access to glucagon-like peptide-1 (GLP-1) medications; legislation seeks to legalize therapeutic use of psychedelics in California.
Read More